Dow 30 Component, The Coca-Cola Company (KO), is the largest total beverage company in the world. It offers 500 plus brands in over 200 countries and is committed to reducing sugar in its drinks and providing new and diverse drinks to people everywhere.
As per reports, Coca-Cola along with its strategic bottling partners Coca-Cola HBC and Coca-Cola European Partners (CCEP) is set to invest €15m in a paperboard packaging solution, KeelClip to replace shrink wrap on can multipacks across Europe by the end of 2021. The move is scheduled to start in Ireland and Poland early next year, followed by Austria, Italy, Switzerland, and Romania in 2020. The initiative to save 2,000 tonnes of plastic and 3,000 tonnes of CO2 annually.
CCEP’s vice president for sustainability Joe Franses stated: “Innovation is a key principle of our sustainable packaging work and the application of this fully recyclable paperboard KeelClip, which comprises a top board that the cans clip into and a central cardboard ‘keel’ – similar to a ship’s keel – that stabilizes the pack, is another example of how we are delivering on our commitment to remove all unnecessary and hard to recycle single-use plastic from our products.”
Reportedly in September, CCEP declared it would end the use of shrink-wrapped plastics across all can multipacks in Great Britain and replace the packaging with 100% recyclable cardboard from Forest Stewardship Council (FSC) or Programme for the Endorsement of Forest Certification (PEFC) certified sources. Coca-Cola intends to make all bottles globally with an average of 50% recycled content by 2030 after the company was named as the world’s largest corporate plastic polluter last year with three million tonnes of plastic usage in its global operations in 2018.
Worldwide, the fertility treatment market is severely underserved. Currently, only 1% to 2% of the estimated 150 million infertile couples worldwide are treated, with the primary prohibiting factor being cost and access to treatment. With this in mind, the business, art, & the science of getting pregnant is receiving greater focus from venture capitalists, private equity firms, mutual funds, and family offices. This interest is evidenced in the increasing number of startups innovating in the fertility space in recent years.
INVO Bioscience, Inc. (IVOB), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world’s only in vivo Intravaginal Culture System (pictured above), announced recently the receipt of a CE Mark for its INVOcell culture and retention device. The receipt of the CE Mark is the final requirement for INVO Bioscience to begin commercially distributing the revolutionary alternative to traditional IVF through the entire European Union.
“We are extremely pleased to receive this very important product certification, the CE Mark, which permits us to commercially distribute the world’s only in vivo fertilization treatment to the millions of patients throughout the countries of the EU. The European countries represent a large potential market for INVOcell, with an estimated $3 to $4 billion currently spent on IVF treatments. Importantly, INVOcell is a simple and more natural solution with the potential to expand the overall addressable market for treatment due to its ability to lower costs compared to IVF while also demonstrating comparable rates of effectiveness. We are currently in the middle of active discussions with several distribution partners around the world, including within the European market, and look forward to providing updates on our international efforts in the near future”, stated Steve Shum, CEO of INVO Bioscience.